(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of 131.29% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Scynexis's revenue in 2025 is $3,258,000.On average, 1 Wall Street analysts forecast SCYX's revenue for 2025 to be $67,918,404, with the lowest SCYX revenue forecast at $67,918,404, and the highest SCYX revenue forecast at $67,918,404. On average, 1 Wall Street analysts forecast SCYX's revenue for 2026 to be $4,789,086,010, with the lowest SCYX revenue forecast at $4,789,086,010, and the highest SCYX revenue forecast at $4,789,086,010.
In 2027, SCYX is forecast to generate $1,689,994,372 in revenue, with the lowest revenue forecast at $1,689,994,372 and the highest revenue forecast at $1,689,994,372.